Comparative Pharmacology
Head-to-head clinical analysis: APADAZ versus NUBAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APADAZ versus NUBAIN.
APADAZ vs NUBAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
APADAZ is a combination of benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. Hydrocodone acts as a full mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception. Acetaminophen's mechanism involves inhibition of cyclooxygenase (COX) enzymes, particularly in the CNS, and modulation of serotonergic pathways, contributing to analgesia and antipyresis.
Nalbuphine is a mixed opioid agonist-antagonist. It acts as an agonist at kappa opioid receptors and as an antagonist at mu opioid receptors, providing analgesia with a ceiling effect for respiratory depression.
Each tablet contains benzhydrocodone 4.08 mg (hydrocodone 3.33 mg) and acetaminophen 325 mg. One to 2 tablets every 4 to 6 hours as needed for pain; maximum 12 tablets per 24 hours.
10-20 mg IV, IM, or SC every 3-6 hours as needed for pain; maximum single dose 20 mg, maximum daily dose 160 mg.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours for benzhydrocodone; context: immediate-release, dosing every 4-6 hours.
3.5–5 hours (terminal elimination half-life); clinically, in hepatic or renal impairment, half-life may be prolonged, requiring dose adjustment.
Renal: ~90% as conjugates, ~10% unchanged; fecal: minimal; enterohepatic recirculation occurs.
Primarily renal (83% as unchanged drug and glucuronide conjugate); fecal excretion accounts for <5%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic